North America Continuous Glucose Monitoring Market: Growth Opportunities, and Demand Forecast Forecast 2025-2034

Overview of the North America Continuous Glucose Monitoring Market

The North America continuous glucose monitoring (CGM) market is witnessing rapid growth due to the rising prevalence of diabetes, increasing awareness of glucose management, and ongoing product innovations. In 2024, the market was valued at USD 6.56 billion, with the United States and Canada holding significant shares. CGM systems are wearable devices that provide real-time glucose readings, enabling better diabetes management compared to traditional finger-prick tests.

Get a free sample report: https://bit.ly/4oSm5jV

The market's expansion is supported by favorable healthcare policies, improved reimbursement frameworks, and a growing shift toward minimally invasive and non-invasive glucose monitoring solutions. With continuous advancements in sensor accuracy, device lifespan, and integration with smartphones and insulin pumps, CGM technology is transforming diabetes care across North America.

The market is projected to grow at a CAGR of 14.50% from 2025 to 2034, reaching USD 25.41 billion by the end of the forecast period.

Size and Share of the North America Continuous Glucose Monitoring Market

In 2024, the North America CGM market accounted for a major share of the global market due to advanced healthcare infrastructure, high diabetes prevalence, and early adoption of digital health solutions. The United States remains the largest market in the region, driven by:

High Diabetes Burden - According to the CDC, over 38 million Americans have diabetes, and millions more are at risk of developing it.

Strong Industry Presence - Leading CGM manufacturers like Abbott, Dexcom, and Medtronic are headquartered or have major operations in the region.

High Consumer Awareness - Extensive diabetes education programs encourage CGM adoption among both Type 1 and Type 2 diabetes patients.

In 2024, the USD 6.56 billion valuation was heavily concentrated in the U.S., followed by Canada, which is showing rapid growth due to government-funded diabetes programs and technology adoption.

Market Dynamics and Trends

Key Drivers

Rising Diabetes Prevalence
The surge in diabetes cases, driven by sedentary lifestyles, obesity, and aging populations, is a major driver of CGM demand.

Technological Advancements
Modern CGMs offer longer sensor wear times, improved accuracy, wireless data transfer, and smartphone integration, enhancing patient convenience.

Favorable Reimbursement Policies
Medicare and private insurers are expanding coverage for CGM devices, encouraging wider adoption.

Integration with Insulin Delivery Systems
The trend of combining CGM devices with insulin pumps for automated insulin delivery is improving disease management outcomes.

Restraints

High Cost of Devices - CGMs remain expensive for uninsured patients, limiting penetration.

Calibration Requirements - Some devices still require occasional fingerstick calibration, which can be inconvenient.

Data Privacy Concerns - As CGMs become more connected, concerns about data security are emerging.

Emerging Trends

Non-Invasive CGMs - Next-generation devices aim to monitor glucose without penetrating the skin.

AI and Predictive Analytics - Artificial intelligence is being used to predict glucose trends, alerting users before dangerous fluctuations occur.

Wearable Ecosystem Integration - CGMs are increasingly pairing with fitness trackers and smartwatches for holistic health monitoring.

Read full report with table of content: https://bit.ly/4oBRHtA

Growth Outlook

The market is expected to grow from USD 4.5 billion in 2025 to USD 25.41 billion by 2034, at a robust CAGR of 14.50%.

Key factors fueling growth include:

Expansion of reimbursement coverage for Type 2 diabetes patients.

Miniaturization and improved comfort of CGM devices.

Growth in telehealth services that integrate CGM data for remote patient monitoring.

Given the increasing healthcare burden of diabetes, CGM adoption is set to become standard practice in North American diabetes care.

Market Opportunities and Challenges

Opportunities

Expansion into Type 2 Diabetes Market
Historically focused on Type 1 patients, CGM adoption among Type 2 diabetics is rapidly increasing.

Remote Patient Monitoring Growth
The use of CGMs in telemedicine platforms allows physicians to monitor patients without in-person visits.

Emerging Pediatric Applications
The pediatric diabetes segment is growing, with parents seeking better glucose control for children.

Integration with Digital Health Platforms
Partnerships with app developers can enhance CGM data visualization and patient engagement.

Challenges

Affordability - High device and sensor costs remain a barrier, especially for uninsured populations.

Technical Limitations - Sensor lifespan and occasional inaccuracies can impact user experience.

Regulatory Hurdles - Devices require strict FDA clearance, which can slow innovation.

User Training Needs - Proper use and interpretation of CGM data require patient education.

Recent Developments

Abbott launched the FreeStyle Libre 3 with enhanced accuracy and smartphone integration in 2024.

Dexcom received FDA approval for the Dexcom G7, which offers faster warm-up times and improved wearability.

Medtronic introduced a next-generation Guardian 4 Sensor, compatible with its MiniMed insulin pump system.

Senseonics expanded its Eversense E3 implantable CGM availability, offering a 180-day wear period.

Byram Healthcare expanded its CGM distribution network in North America to improve access.

These innovations reflect a strong focus on accuracy, comfort, and integration with digital health tools.

Market Growth Projection

By 2034, the market's projected size of USD 25.41 billion will be driven by:

Wider insurance coverage.

Technological breakthroughs in non-invasive sensors.

Increasing demand for integrated diabetes management solutions.

Competitor Analysis

Key Players in the North America Continuous Glucose Monitoring Market

Abbott - Known for the FreeStyle Libre series, a market leader in sensor-based glucose monitoring.

Dexcom, Inc. - Offers high-performance real-time CGM systems like the G7 with advanced data analytics.

Medtronic PLC - Integrates CGM sensors with insulin pumps for automated insulin delivery.

Senseonics, Inc. - Specializes in long-term implantable CGMs such as the Eversense E3.

Byram Healthcare Centers, Inc. - A major distributor of diabetes care products, including CGM devices.

Hoffmann-La Roche Limited - Provides diabetes monitoring solutions and is investing in connected health platforms.

Frequently Asked Questions (FAQs)

. What is the North America continuous glucose monitoring market size?
The market was valued at USD 6.56 billion in 2024 and is projected to reach USD 25.41 billion by 2034.

. What is the growth rate of the market?
It is expected to grow at a CAGR of 14.50% between 2025 and 2034.

. What factors are driving market growth?
Rising diabetes prevalence, product innovations, and expanded insurance coverage are key growth drivers.

. Which countries dominate the market?
The United States holds the largest share, followed by Canada.

. What are the major challenges?
High device costs, technical limitations, and regulatory requirements are primary challenges.

. Who are the key players?
Abbott, Dexcom, Medtronic, Senseonics, Byram Healthcare, and Hoffmann-La Roche are leading companies.

. Are CGMs covered by insurance?
Yes, Medicare and many private insurers provide coverage for CGM devices.

. What is the latest technology trend?
Non-invasive CGM devices and AI-driven predictive analytics are emerging trends.

. Can CGMs be used by Type 2 diabetes patients?
Yes, CGM adoption is increasing among Type 2 diabetes patients for better glucose control.

. What is the future outlook?
With growing healthcare awareness and continuous innovation, CGMs are expected to become a standard tool for diabetes management in North America.

Find More Report:

Metagenomics Market: https://bit.ly/4o1wjxM

Tele-ICU Market: https://bit.ly/4lyqSVo

Cancer Pain Market: https://bit.ly/46mIb77

DNA Microarray Market: https://bit.ly/46m6aU7

CB Oil Market: https://bit.ly/417PmMW

Media Contact:

Company Name: Claight Corporation
Contact Person: Deepanshu Choudhary, Digital Marketing
Email: sales@expertmarketresearch.com
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others. Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

This release was published on openPR.